In an effort to encourage widespread STD screening to help slow the transmission of these infections and promote more responsive and effective patient care,
Seegene, Rockville, Md, introduced a new STD/HPV diagnostic test capable of simultaneously detecting the most common bacteria and viruses causing STDs.
The new Seeplex STD/HPV test screens for Chlamydia Trachomatis (CT), Neisseria Gonorrhea (NG), as well as 14 Human Papillomaviruses (HPV) high risk types and five HPV low risk types in a single reaction tube, at the price point of a single pathogen test using the same sample.
Current clinical STD and HPV screening procedures use a separate test to detect each indication for CT, NG, HPV High Risk, and HPV Low Risk. Since STD infections have a high coinfection rate (with afflicted individuals exhibiting more than one STD infection), and HPV is the main cause of cervical cancer, clinical health care systems need an effective and economical diagnostic tool capable of detecting the most prevalent STD and HPV pathogens with a single test.
“Since most STD and HPV cause no noticeable symptoms, they go undetected. These asymptomatic infections can be diagnosed only through testing,” said Jong-Yoon Chun, founder and CEO of Seegene. “Therefore, the only way to slow the spread of STD/HPV along with their dangerous effects, like cervical cancer, is to provide routine and ubiquitous screening programs.”
Seeplex is a multiplexing PCR technology that enables a new standard in simultaneous multipathogen detection. Seegene applies its proprietary system utilizing Dual Priming Oligo (DPO) and Annealing Control Primer (ACP) to create multipathogen tests delivering maximum specificity, reproducibility and sensitivity.
Experts here are available to answer all your questions!
